MAGELLAN LONGEVITY
HomeNutraceuticals & Cellular Energizers › Palmitoylethanolamide (PEA)

Palmitoylethanolamide (PEA)

Written and medically reviewed by , physiatrist · Last reviewed · How we grade
In one paragraph

Palmitoylethanolamide (PEA), graded Moderate-evidence on Magellan — commercial supplements are usually synthetic and are frequently sold in micronized or ultra-micronized forms intended to improve absorption. Honest appraisal matters: effect sizes vary widely, several analyses flag very high heterogeneity, low study quality and possible publication bias, and a geriatric N-of-1 trial found only a small effect, so PEA is best viewed as a promising adjunct rather than a proven stand-alone therapy.

Source: Pain Physician 2017, PMID 28727699 ↗ · Nutraceuticals & Cellular Energizers · How Magellan grades evidence · Study write-up · evidence confidence: high

Nutraceuticals & Cellular Energizers18 PubMed citations
$76.99 typical listed price — check the live price on Amazon
View Palmitoylethanolamide (PEA) on Amazon ↗   Open in the Magellan store →

What it is

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide of the N-acylethanolamine family that is produced on demand from cell-membrane phospholipids and is also present in foods such as egg yolk, soybeans and peanuts. It acts chiefly as an agonist of the nuclear receptor PPAR-alpha and down-modulates the activation of mast cells and glial cells, producing anti-inflammatory, analgesic and neuroprotective effects. Because it engages endocannabinoid-related pathways without binding the classical cannabinoid receptors, it is often described as a cannabinoid-like or 'ALIAmide' compound. Commercial supplements are usually synthetic and are frequently sold in micronized or ultra-micronized forms intended to improve absorption.

Its role in longevity

Across randomized trials and several meta-analyses, oral PEA has been associated with reductions in chronic pain of mixed origin, including neuropathic, nociceptive/musculoskeletal (e.g., knee osteoarthritis and temporomandibular joint pain) and pelvic pain from endometriosis, and it is generally well tolerated, with benefit often taking one to two months to appear. Honest appraisal matters: effect sizes vary widely, several analyses flag very high heterogeneity, low study quality and possible publication bias, and a geriatric N-of-1 trial found only a small effect, so PEA is best viewed as a promising adjunct rather than a proven stand-alone therapy. Additional relevance to aging comes from mechanistic and animal studies showing reduced neuroinflammation and, in aged mice, neuroprotective and survival benefits, though these remain preclinical. This evidence describes the palmitoylethanolamide compound and its mechanisms, not this specific commercial product.

The research

Peer-reviewed studies on the active compound — citations link to PubMed.

“PEA was associated with significantly greater pain reduction compared to inactive control conditions (P < 0.001)… PEA may be a useful treatment for pain and is generally well tolerated.”
Pain Physician 2017 · PMID 28727699
“PEA was found to reduce pain scores relative to comparators in a pooled estimate, with a standard mean difference of 1.68 (95% CI 1.05 to 2.31, p = 0.00001).”
Nutrients 2023 · PMID 36986081
“These two obtained scores corresponded to a 35.1% pain intensity reduction within the first month, followed by a further 35.4% during the second month.”
Nutrients 2024 · PMID 38892586
“This meta-analysis confirmed that PEA effectively reduces pain and enhances quality of life, with significant benefits observed within 4-6 weeks of treatment.”
Nutr Rev 2025 · PMID 39798151
“PEA was found to reduce pain scores relative to comparators in a pooled estimate, with a standardized mean difference of 1.68 (95% CI 1.05 to 2.31). The results suggest that PEA is an effective and well-tolerated treatment for chronic pain.”
Nutrients 2023 · PMID 36986081
“However, the results are downgraded due to the high heterogeneity of the studies (I2 = 99%), and the funnel plot suggests publication bias.”
Pharmaceutics 2022 · PMID 36015298

Research describes the active mechanism and is not a claim about this specific product.

Educational information, not medical advice. This product is not intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if pregnant, nursing, or taking medication.

More in Nutraceuticals & Cellular Energizers

Omega-3 EPA/DHA Fish Oil

Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum…

Creatine Monohydrate

Across meta-analyses and randomized trials, creatine monohydrate combined with…

Astaxanthin Softgels

In humans, randomized trials and meta-analyses most consistently show that astaxanthin…

Zinc Picolinate

Multiple meta-analyses of randomized trials indicate that oral zinc, started soon after…

See all Nutraceuticals & Cellular Energizers →

FAQ

Does Palmitoylethanolamide (PEA) have scientific evidence?

Yes — its active compound is linked to 18 peer-reviewed studies, summarized and cited above.

Where can I buy Palmitoylethanolamide (PEA)?

You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.

Is Palmitoylethanolamide (PEA) safe?

Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.